BRPI0416123B8 - composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção - Google Patents

composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção

Info

Publication number
BRPI0416123B8
BRPI0416123B8 BRPI0416123A BRPI0416123A BRPI0416123B8 BR PI0416123 B8 BRPI0416123 B8 BR PI0416123B8 BR PI0416123 A BRPI0416123 A BR PI0416123A BR PI0416123 A BRPI0416123 A BR PI0416123A BR PI0416123 B8 BRPI0416123 B8 BR PI0416123B8
Authority
BR
Brazil
Prior art keywords
composition
ophthalmic
treating
inflammation
infection
Prior art date
Application number
BRPI0416123A
Other languages
English (en)
Inventor
Krishnamoorthy Ramesh
Original Assignee
Bausch & Lomb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch & Lomb filed Critical Bausch & Lomb
Publication of BRPI0416123A publication Critical patent/BRPI0416123A/pt
Publication of BRPI0416123B1 publication Critical patent/BRPI0416123B1/pt
Publication of BRPI0416123B8 publication Critical patent/BRPI0416123B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção". a presente invenção refere-se a formulações para uso tópico, compreendendo antibióticos em combinação com esteróides antiinflamatórios para o tratamento de infecções oftálmicas e inflamação contínua. mais especificamente, a presente invenção refere-se à formulações farmacêuticas oftálmicas compreendendo uma quantidade estabilizadora de ph, constituída de tobramicina e esteróide brando de etabonato de loteprednol.
BRPI0416123A 2003-10-31 2004-10-27 composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção BRPI0416123B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/698,322 US20050095205A1 (en) 2003-10-31 2003-10-31 Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
PCT/US2004/035562 WO2005044231A1 (en) 2003-10-31 2004-10-27 Suspension of loteprednol etabonate and tobramycin for topical ophthalmic use

Publications (3)

Publication Number Publication Date
BRPI0416123A BRPI0416123A (pt) 2007-01-02
BRPI0416123B1 BRPI0416123B1 (pt) 2018-11-21
BRPI0416123B8 true BRPI0416123B8 (pt) 2021-05-25

Family

ID=34550614

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416123A BRPI0416123B8 (pt) 2003-10-31 2004-10-27 composição antiinflamatória e composição antiinfecciosa para uso oftálmico ou otolaringológico e método para tratar a dita inflamação e infecção

Country Status (13)

Country Link
US (2) US20050095205A1 (pt)
EP (1) EP1677761B1 (pt)
JP (2) JP2007509952A (pt)
KR (1) KR101086990B1 (pt)
CN (1) CN1897917A (pt)
AT (1) ATE391493T1 (pt)
AU (1) AU2004287443B2 (pt)
BR (1) BRPI0416123B8 (pt)
CA (1) CA2544139C (pt)
DE (1) DE602004013035T2 (pt)
ES (1) ES2303967T3 (pt)
TW (1) TWI359022B (pt)
WO (1) WO2005044231A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20050197303A1 (en) * 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
WO2007032997A1 (en) * 2005-09-13 2007-03-22 Bausch & Lomb Incorporated Ophthalmic formulation containing loteprednol etabonate for treatment of dry eye
US20070093461A1 (en) * 2005-10-26 2007-04-26 Bausch & Lomb Incorporated Effect of Loteprednol etabonate on vascular dysfunction
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
EP2003970A4 (en) * 2006-03-28 2012-07-11 Javelin Pharmaceuticals Inc FORMULATIONS OF LOW-DOSEED NON-STEROID INFLAMMATORY INHIBITORS AND BETA-CYCLODEXTRIN
AU2007230716B2 (en) * 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
CN101317847B (zh) * 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
US20090239836A1 (en) * 2008-03-24 2009-09-24 Mary Lee Ciolkowski Multifunctional Ophthalmic Compositions
CN102118973A (zh) * 2008-06-12 2011-07-06 前瞻生物治疗公司 一种眼科组合物中新的防腐剂替代物聚维酮碘
WO2012073856A1 (ja) * 2010-11-29 2012-06-07 千寿製薬株式会社 ジフルプレドナートおよびトブラマイシンを含有する水中油型エマルジョン組成物
WO2013065028A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
HK1208162A1 (en) 2012-05-03 2016-02-26 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2013166408A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
SG11201809811VA (en) * 2016-05-05 2018-12-28 Veloce Biopharma Llc Compositions and methods for treatment of inflammation or infection of the eye
US10555947B2 (en) * 2017-05-19 2020-02-11 Ocugen, Inc. Ophthalmic compositions and methods of use

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4996335A (en) * 1980-07-10 1991-02-26 Nicholas S. Bodor Soft steroids having anti-inflammatory activity
US4710495A (en) * 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
US6610675B1 (en) * 1980-07-10 2003-08-26 Nicholas S. Bodor Inactive metabolite approach to soft drug design
US5192535A (en) * 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
US5149693A (en) * 1988-03-09 1992-09-22 Alcon Laboratories, Inc. Combination of tobramycin and fluorometholone for topical ophthalmic use
US5340572A (en) * 1993-02-08 1994-08-23 Insite Vision Incorporated Alkaline ophthalmic suspensions
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
TW503113B (en) * 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
JP3147076B2 (ja) * 1997-03-14 2001-03-19 千寿製薬株式会社 ロテプレドノール エタボネート水性懸濁液
KR100508227B1 (ko) * 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 로테프레드놀에타보네이트수성현탁액
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US20020098154A1 (en) * 2001-01-20 2002-07-25 Dyer Gordon Wayne Methods and apparatus for medicating the nasal sinuses
MXPA05013898A (es) * 2003-06-19 2006-05-25 Nicholas S Bodor Mejoramiento de la actividad y/o duracion de la accion de esteroides antiinflamatorios suaves para la aplicacion topica u otra aplicacion local.
US20050095205A1 (en) * 2003-10-31 2005-05-05 Ramesh Krishnamoorthy Combination of loteprednol etabonate and tobramycin for topical ophthalmic use

Also Published As

Publication number Publication date
EP1677761A1 (en) 2006-07-12
CA2544139C (en) 2012-10-09
CA2544139A1 (en) 2005-05-19
ATE391493T1 (de) 2008-04-15
JP2012087151A (ja) 2012-05-10
TW200526235A (en) 2005-08-16
EP1677761B1 (en) 2008-04-09
KR101086990B1 (ko) 2011-11-29
AU2004287443A1 (en) 2005-05-19
US20100003334A1 (en) 2010-01-07
BRPI0416123A (pt) 2007-01-02
DE602004013035D1 (de) 2008-05-21
WO2005044231A1 (en) 2005-05-19
US20050095205A1 (en) 2005-05-05
BRPI0416123B1 (pt) 2018-11-21
KR20060110312A (ko) 2006-10-24
ES2303967T3 (es) 2008-09-01
JP5726774B2 (ja) 2015-06-03
CN1897917A (zh) 2007-01-17
DE602004013035T2 (de) 2009-05-07
JP2007509952A (ja) 2007-04-19
TWI359022B (en) 2012-03-01
AU2004287443B2 (en) 2011-01-27
HK1092354A1 (en) 2007-02-09

Similar Documents

Publication Publication Date Title
ATE391493T1 (de) Suspension von loteprednol-etabonat und tobramycin für die topische ophthalmische anwendung
HK1038693A1 (zh) 治疗眼、耳、鼻病症的抗生素合成剂
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
IL177816A (en) Compositions and kits for topical application and transdermal delivery of botulinum toxins
WO2001089496A3 (en) Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
UA89793C2 (uk) Фармацевтична композиція, яка містить антибіотик, триазол і кортикостероїд
WO2005096990A3 (en) Novel modification of medical prostheses
RU2010123052A (ru) Авенантрамидсодержащие композиции
BRPI0211282B8 (pt) curativo compreendendo composição de fluido de silicone não volátil e seu método de manufatura, uso de composição para tratamento de cicatriz e de infecção por patógeno, bem como aplicador
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2005007072A3 (en) Methods and pharmaceutical compositions for healing wounds
WO2010119364A3 (en) A medicinal cream made using neomycin sulphate, betamethasone valerate, and chitosan, and a process to make the same
AR016504A1 (es) Composicion proteica estabilizada, forma farmaceutica de dosificacion, un metodo para preparar una forma farmaceutica de dosificacion, uso de la composicion proteica en la fabricacion de medicamentos y kit
DK1440148T3 (da) Keratinocytter anvendelige som biologisk aktive substanser i behandling af sår
SE0300971D0 (sv) Nitric oxide in treatment of inflammation
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
NO20025157L (no) Kreftterapi
CL2004001012A1 (es) Compuestos derivados de macrolidos de 14 o 15 miembros, sustituidos en posicion 4"; procedimiento para su preparacion; composicion farmaceutica que lo comprende; y su uso para el tratamiento o profilaxis de infecciones microbianas sistemicas o topica
BRPI0715361B8 (pt) uso de polietileno glicol em inflamação relacionada com doenças ou distúrbios tópicos e cicatrização de ferimento
BRPI0413770A (pt) uso isolado de tigeciclina ou em combinação com rinfampin para tratar osteomielite e/ou artrite séptica
AU2002221365A1 (en) Pharmaceutical composition for treatment of phimosis using topical corticosteroid
CA2420640A1 (en) Combination preparations of 3-n-formyl hydroxy amino propyl phosphonic acid derivatives or 3-n-acetyl hydroxy amino propyl phosphonic acid derivatives together with special pharmaceutical active ingredients

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA:INT.CI. A61K 9/10, A61K 31/56, A61K 31/7036, A61P 27/02

Ipc: A61K 9/10 (2011.01), A61K 31/56 (2011.01), A61K 31

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8, 13 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2855 DE 23/09/2025 POR TER SIDO INDEVIDA.